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BACKGROUND
Neurodegenerative disorders have been reported in elite athletes who participated in 
contact sports. The incidence of neurodegenerative disease among former professional 
soccer players has not been well characterized.
METHODS
We conducted a retrospective cohort study to compare mortality from neurodegenerative 
disease among 7676 former professional soccer players (identified from databases of 
Scottish players) with that among 23,028 controls from the general population who were 
matched to the players on the basis of sex, age, and degree of social deprivation. Causes 
of death were determined from death certificates. Data on medications dispensed for the 
treatment of dementia in the two cohorts were also compared. Prescription information 
was obtained from the national Prescribing Information System.
RESULTS
Over a median of 18 years, 1180 former soccer players (15.4%) and 3807 controls (16.5%) died. 
All-cause mortality was lower among former players than among controls up to the age of 
70 years and was higher thereafter. Mortality from ischemic heart disease was lower among 
former players than among controls (hazard ratio, 0.80; 95% confidence interval [CI], 0.66 to 
0.97; P = 0.02), as was mortality from lung cancer (hazard ratio, 0.53; 95% CI, 0.40 to 0.70; 
P<0.001). Mortality with neurodegenerative disease listed as the primary cause was 1.7% 
among former soccer players and 0.5% among controls (subhazard ratio [the hazard ratio 
adjusted for competing risks of death from ischemic heart disease and death from any cancer], 
3.45; 95% CI, 2.11 to 5.62; P<0.001). Among former players, mortality with neurodegenerative 
disease listed as the primary or a contributory cause on the death certificate varied according 
to disease subtype and was highest among those with Alzheimer’s disease (hazard ratio 
[former players vs. controls], 5.07; 95% CI, 2.92 to 8.82; P<0.001) and lowest among those with 
Parkinson’s disease (hazard ratio, 2.15; 95% CI, 1.17 to 3.96; P = 0.01). Dementia-related 
medications were prescribed more frequently to former players than to controls (odds ratio, 
4.90; 95% CI, 3.81 to 6.31; P<0.001). Mortality with neurodegenerative disease listed as the 
primary or a contributory cause did not differ significantly between goalkeepers and outfield 
players (hazard ratio, 0.73; 95% CI, 0.43 to 1.24; P = 0.24), but dementia-related medications 
were prescribed less frequently to goalkeepers (odds ratio, 0.41; 95% CI, 0.19 to 0.89; P = 0.02).
CONCLUSIONS
In this retrospective epidemiologic analysis, mortality from neurodegenerative disease 
was higher and mortality from other common diseases lower among former Scottish 
professional soccer players than among matched controls. Dementia-related medications 
were prescribed more frequently to former players than to controls. These observations 
need to be confirmed in prospective matched-cohort studies. (Funded by the Football 
Association and Professional Footballers’ Association.)
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Concerns have been raised about the risk of several neurodegenerative dis-eases, such as Alzheimer’s disease, amyo-
trophic lateral sclerosis, and chronic traumatic 
encephalopathy (CTE), associated with partici-
pation in contact sports.1-3 Recognition of the 
pathologic changes of CTE in former players 
who participated in a range of contact sports,4-8 
including American football4,5 and soccer,6,9-13 has 
partly led to these concerns. Data regarding the 
risk of neurodegenerative disease among former 
professional soccer players are limited.
The neurocognitive consequences of partici-
pation in contact sports are uncertain, but the 
overall health benefits of physical activity in the 
prevention of chronic diseases, including demen-
tia,14 and in the reduction in mortality15,16 have 
been established. Studies have also shown that 
participants in elite-level sports have evidence of 
lifelong health benefits,17 including lower all-
cause mortality18 and lower risk of cardiovascu-
lar disease19 than the general population.
Soccer is played in over 200 countries by more 
than a quarter of a billion people.20 Although 
casual and amateur play is not comparable to 
professional soccer, information on health out-
comes among former professional players may 
be valuable to inform the management of risks 
in the sport. We conducted a retrospective co-
hort study to compare mortality from neurode-
generative disease among Scottish former profes-
sional soccer players with that among matched 
controls from the general population.
Me thods
Study Oversight
This study was approved by the College of 
Medical, Veterinary, and Life Sciences Ethics 
Committee, University of Glasgow. The protocol, 
which has been previously published,21 and data-
governance procedures were reviewed and ap-
proved by National Health Service (NHS) Scot-
land Public Benefit and Privacy Panel for Health 
and Social Care. All data from health records 
were deidentified by an independent informa-
tion analyst who worked in the electronic Data 
Research and Innovation Service of NHS Scot-
land; participant-level consent was not required. 
The results from this study were analyzed and 
reported in accordance with the Strengthening 
the Reporting of Observational Studies in Epide-
miology (STROBE) guidelines.22 The authors vouch 
for the accuracy and completeness of the data 
and for the fidelity of the study to the protocol.
Inclusion Criteria
We accessed electronic health records to obtain 
data on death certification and medications that 
are typically prescribed for the treatment of de-
mentia in a cohort of former professional soccer 
players. Former professional soccer players were 
identified from databases of all Scottish profes-
sional soccer players23,24 that were compiled from 
the archives of the Scottish Soccer Museum and 
the individual league clubs. Available data in-
cluded the full name and date of birth of the 
players and career information, including dates 
of first signing and retirement, number of match 
appearances, and player position. These data-
bases were merged, and duplicate entries deleted. 
Persons born before January 1, 1977, were eli-
gible for inclusion in the study. All the former 
soccer players were male.
Probabilistic matching was applied to the full 
name and date of birth of former soccer players 
to link them to their unique Community Health 
Index numbers. Variables such as date of birth 
and full name were compared between former 
players and Community Health Index data sets, 
and a score was attached to each matched vari-
able that reflected the level of agreement. The 
scores for each variable were summed to gener-
ate an overall score, which correlated with the 
likelihood of the two records belonging to the 
same person. An automated computer program 
was used to match former players with controls 
from the general population, in a 1:3 ratio, on 
the basis of sex, year of birth, and degree of 
social deprivation. To match the degree of social 
deprivation between cohorts, we used records 
from the NHS Information Services Division, 
which contain the last known postal code of 
residence for all persons. For each area of resi-
dence, data on social deprivation were derived 
with the use of postal code–level data on income, 
employment, health, education, housing, access to 
local amenities, and crime and were categorized 
into quintiles on the basis of the Scottish Index 
of Multiple Deprivation (SIMD), with the quin-
tiles ranging from 1 (most deprived) to 5 (least 
deprived).25
The Community Health Index number can be 
linked to death certificates and records in the 
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national Prescribing Information System. Infor-
mation recorded on death certificates includes 
the date of death and the primary and contribu-
tory causes of death, coded according to the Inter-
national Classification of Diseases, 9th Revision and 
10th Revision (ICD-9 and ICD-10). The Prescribing 
Information System documents every prescription 
dispensed in the community and has included 
complete Community Health Index data since 
2009; medications are coded according to the 
British National Formulary.26 The ICD-9 and 
ICD-10 codes that were used to identify out-
comes as death with neurodegenerative disease 
listed as the primary or a contributory cause 
(classified as all neurodegenerative diseases, de-
mentia not otherwise specified, Alzheimer’s dis-
ease, non-Alzheimer’s dementias, motor neuron 
disease, and Parkinson’s disease) and the remain-
ing most common causes of death in the Scot-
tish adult male population (diseases of the circu-
latory system [classified as all diseases of the 
circulatory system, ischemic heart disease, and 
stroke or cerebrovascular disease], diseases of 
the respiratory system, or cancer [classified as 
any cancer or lung cancer]) are provided in Table 
S1 in the Supplementary Appendix, available with 
the full text of this article at NEJM.org. Because 
no ICD-9 or ICD-10 codes exist for CTE or its 
synonym, dementia pugilistica, these diagnoses 
were not identifiable from death certificate re-
cords. The medications included in the analysis 
of medications for dementia are listed in Section 
4.11 of the British National Formulary and in 
Table S2. All analyses included data up to De-
cember 31, 2016, and the database interrogation 
was performed on December 10, 2018.
Statistical Analysis
We used Cox proportional-hazards regression to 
model time to death and Schoenfeld residuals to 
test the assumption of proportional hazards.27 
When the assumption of proportional hazards 
did not hold, a time-varying model was used to 
derive hazard ratios over different periods of 
follow-up.28 Age was used as the time covariate, 
with follow-up from age 40 years to the date of 
data censoring, which was either the date of 
death or the end of follow-up (December 31, 
2016), whichever occurred first. In a sensitivity 
analysis, the outcome of death from neurode-
generative disease was subjected to a competing-
risks regression analysis to ascertain whether 
the estimated hazard ratio was sensitive to the 
competing risks of death from ischemic heart 
disease and death from any cancer.29 We tested 
the assumption of proportional subhazards (haz-
ard ratios adjusted for competing risks of death 
from ischemic heart disease and death from any 
cancer) by including an interaction term between 
time of analysis and a dummy variable for for-
mer soccer player status and assessing whether 
the interaction was significant (P<0.05). The mor-
tality models were repeated in the analysis of the 
subgroups of former players defined according 
to player position (outfield player or goalkeeper). 
Because prescribing outcomes were available only 
from 2009 onward, we applied a nested case–
control design in which conditional logistic 
regression was used to analyze the whole cohort 
(matched data)30 and standard logistic regression 
was used to analyze the subgroups of former 
players defined according to player position. All 
statistical analyses were performed with the use 
of Stata/MP software, version 14.1 (StataCorp). 
Two-sided P values of less than 0.05 were consid-
ered to indicate statistical significance.
R esult s
Study Cohorts
A total of 9670 records of former professional 
soccer players were identified from the player 
databases; 7676 of the 9670 records were suc-
cessfully matched to Community Health Index 
numbers, which permitted the identification of 
23,028 matched controls (Table 1). The remain-
ing 1994 records could not be matched to a Com-
munity Health Index number because of duplicate 
entries (170 records) or incomplete or inaccurate 
demographic information (1824 records) (Fig. S1). 
During a median follow-up of 18.0 years from 
study entry at the age of 40 years, 1180 former 
soccer players (15.4%) and 3807 matched con-
trols (16.5%) died; the mean (±SD) age at death 
was 67.9±13.0 years and 64.7±14.0 years, respec-
tively.
Primary Cause of Death
All-cause mortality was lower among former 
soccer players than among matched controls 
(hazard ratio, 0.87; 95% confidence interval [CI], 
0.80 to 0.93; P<0.001); however, the proportional-
hazards assumption was not met. A time-depen-
dent analysis showed that mortality was lower 
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among former soccer players than among 
matched controls up to the age of 70 years and 
was higher thereafter (Fig. 1). The analyses of 
death from ischemic heart disease (hazard ratio 
[former players vs. matched controls], 0.80; 95% 
CI, 0.66 to 0.97; P = 0.02) and death from lung 
cancer (hazard ratio, 0.53; 95% CI, 0.40 to 0.70; 
P<0.001) fulfilled the proportional-hazards as-
sumption and showed that mortality from either 
of these causes was lower among former soccer 
players than among matched controls (Table 2).
Mortality with neurodegenerative disease list-
ed as the primary diagnosis on the death certifi-
cate was 1.7% among former soccer players and 
0.5% among matched controls (hazard ratio, 
4.10; 95% CI, 2.88 to 5.83; P<0.001), but after 
adjustment for the competing risks of death 
from ischemic heart disease and death from any 
cancer, this higher mortality was partially attenu-
ated (subhazard ratio, 3.45; 95% CI, 2.11 to 5.62; 
P<0.001) (Table 2). Mortality from stroke or 
cerebrovascular disease did not differ signifi-
cantly between study cohorts (hazard ratio, 0.88; 
95% CI, 0.78 to 1.00; P = 0.06). Analyses of death 
from any cancer (hazard ratio, 0.94; 95% CI, 
0.71 to 1.25) and death from respiratory disease 
(hazard ratio, 0.61; 95% CI, 0.46 to 0.82) did not 
meet the proportional-hazards assumption.
Neurodegenerative Causes of Death  
and Prescriptions of Dementia-Related 
Medications
Neurodegenerative disease was recorded as the 
primary or a contributory cause of death in 222 
former soccer players (2.9%) and 228 matched 
controls (1.0%) (hazard ratio, 3.53; 95% CI, 2.72 
to 4.57; P<0.001). Among former players, the 
estimated risk of death with neurodegenerative 
disease listed as the primary or a contributory 
cause varied according to disease subtype (Ta-
ble 3) and was highest for those with Alzheimer’s 
disease (hazard ratio, 5.07; 95% CI, 2.92 to 8.82; 
P<0.001) and lowest for those with Parkinson’s 
disease (hazard ratio, 2.15; 95% CI, 1.17 to 3.96; 
P = 0.01). Age at death with neurodegenerative 
disease or its subtypes listed as the primary or a 
contributory cause did not differ significantly 
between former soccer players and matched 
controls, other than for non-Alzheimer’s demen-
tia (77.5±7.5 years of age [former players] vs. 
81.3±7.3 years of age [controls]; P = 0.005) (Fig. S2). 
Former soccer players were more likely to receive 
a prescription of a dementia-related medication 
than matched controls (odds ratio, 4.90; 95% CI, 
3.81 to 6.31; P<0.001) (Table 4).
Characteristic
Former Soccer Players 
(N = 7676)
Matched Controls 
(N = 23,028)
number (percent)
SIMD quintile
1 1206 (15.7) 3617 (15.7)
2 1371 (17.9) 4112 (17.9)
3 1449 (18.9) 4349 (18.9)
4 1613 (21.0) 4839 (21.0)
5 2037 (26.5) 6111 (26.5)
Player position
Goalkeeper 598 (7.8) NA
Outfield player 6024 (78.5) NA
Unknown 1054 (13.7) NA
*  The degree of social deprivation was categorized into quintiles on the basis of 
the Scottish Index of Multiple Deprivation (SIMD), with the quintiles ranging 
from 1 (most deprived) to 5 (least deprived).25 NA denotes not applicable.
Table 1. Social Deprivation in the Two Cohorts and Player Positions among 
Former Soccer Players.*
Figure 1. Time-Varying Hazard Ratios for Death from Any Cause among Former 
Soccer Players 40 to 90 Years of Age, as Compared with Matched Controls.
Because the proportional­hazards assumption did not hold for all­cause 
mortality when former professional soccer players were compared with 
matched controls from the general population, a time­dependent analysis 
was performed. This analysis showed that all­cause mortality was lower 
among former professional soccer players up to the age of 70 years and was 
higher thereafter. Time­varying hazard ratios and 95% confidence intervals 
were calculated with the use of the “lincom” command in Stata software.
H
az
ar
d 
R
at
io
2.5
1.5
2.0
1.0
0.5
0.0
30 40 50 60 70 9080 100
Age (yr)
The New England Journal of Medicine 
Downloaded from nejm.org at GLASGOW UNIVERSITY LIBRARY on April 22, 2020. For personal use only. No other uses without permission. 
 Copyright © 2019 Massachusetts Medical Society. All rights reserved. 
n engl j med 381;19 nejm.org November 7, 2019 1805
Neurodegener ative Disease in Former Soccer Players
Influence of Player Position on Mortality 
and Prescriptions of Dementia-Related 
Medications
In the subgroup analysis based on player posi-
tions, mortality with neurodegenerative disease 
listed as the primary or a contributory cause on 
the death certificate did not differ significantly 
between goalkeepers and outfield players (haz-
ard ratio, 0.73; 95% CI, 0.43 to 1.24; P = 0.24). 
Similarly, there was no significant difference be-
tween those groups when the primary or con-
tributory cause was listed as dementia not other-
wise specified (hazard ratio, 0.59; 95% CI, 0.31 
to 1.12; P = 0.10) (Table 4). Dementia-related med-
ications were prescribed less frequently to goal-
keepers than to outfield players (odds ratio, 0.41; 
95% CI, 0.19 to 0.89; P = 0.02) (Table 4).
Discussion
Our data show that all-cause mortality was 
lower in a cohort of Scottish former professional 
soccer players than in a control cohort of adults 
from the general population who were matched 
to the players on the basis of sex, age, and de-
gree of social deprivation. This association was 
age-dependent; mortality was lower among for-
mer soccer players up to the age of 70 years and 
was higher thereafter. Mortality with neurode-
generative disease listed as the primary diagno-
sis on the death certificate was higher among 
the former soccer players than among the con-
trols, a finding that was independent of the 
competing risks of death from ischemic heart 
disease and death from cancer; however, when 
Primary Cause of Death
Former Soccer 
Players 
(N = 7676)
Matched 
Controls 
(N = 23,028)
Hazard Ratio for Death 
(95% CI) P Value*
number (percent)
Any cause† 1180 (15.4) 3807 (16.5) 0.87 (0.80–0.93) <0.001
Ischemic heart disease 173 (2.3) 568 (2.5) 0.80 (0.66–0.97) 0.02
Lung cancer 74 (1.0) 362 (1.6) 0.53 (0.40–0.70) <0.001
Neurodegenerative disease 134 (1.7) 120 (0.5) 4.10 (2.88–5.83)‡ <0.001
*  P values were calculated with the use of a Cox proportional­hazards regression model.
†  An analysis of all­cause mortality did not fulfill the proportional­hazards assumption and showed time­dependent vari­
ability.
‡  In an analysis that included adjustment for competing risks of death from ischemic heart disease and death from can­
cer, the subhazard ratio was 3.45 (95% CI, 2.11 to 5.62) (P<0.001).
Table 2. Primary Cause of Death among Former Soccer Players and Matched Controls.
Primary or Contributory Cause of Death
Former Soccer 
Players 
(N = 7676)
Matched 
Controls 
(N = 23,028)
Hazard Ratio for Death 
(95% CI) P Value*
number (percent)
Any neurodegenerative disease 222 (2.9) 228 (1.0) 3.53 (2.72–4.57) <0.001
Neurodegenerative disease subtype
Dementia not otherwise specified 180 (2.3) 178 (0.8) 3.87 (2.86–5.24) <0.001
Alzheimer’s disease 64 (0.8) 47 (0.2) 5.07 (2.92–8.82) <0.001
Non­Alzheimer’s dementias 121 (1.6) 133 (0.6) 3.48 (2.42–5.00) <0.001
Motor neuron disease 22 (0.3) 17 (0.1) 4.33 (2.05–9.15) <0.001
Parkinson’s disease 28 (0.4) 44 (0.2) 2.15 (1.17–3.96) 0.01
*  P values were calculated with the use of a Cox proportional­hazards regression model.
Table 3. Mortality with Neurodegenerative Disease Listed as the Primary or a Contributory Cause.
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these competing risks were incorporated into the 
analysis, this higher mortality was partially atten-
uated. Among the former players, the estimated 
risk of death with neurodegenerative disease 
listed as the primary or a contributory cause was 
highest for those with Alzheimer’s disease and 
lowest for those with Parkinson’s disease. These 
observations are consistent with our finding that 
dementia-related medications were prescribed 
more frequently to former players than to con-
trols. Mortality with neurodegenerative disease 
listed as the primary or a contributory cause did 
not differ significantly between outfield players 
and goalkeepers; however, dementia-related med-
ications were prescribed more frequently to out-
field players.
The observation of a lower all-cause mortality 
up to the age of 70 years among former profes-
sional soccer players is similar to findings in 
previous studies involving elite athletes who 
participated in a range of sports,17 including soc-
cer,31 and may reflect higher levels of physical 
activity and lower levels of obesity and smoking 
in elite athletes than in the general population. 
In contrast, mortality from neurodegenerative 
disease was higher among former soccer players, 
a finding consistent with studies involving former 
players in the U.S. National Football League.18,32 
Neither CTE nor dementia pugilistica was a coded 
item in ICD-9 or ICD-10, and it was not possible 
to inquire about these causes of death in our 
study. Studies reporting clinicopathological diag-
noses from autopsies in former soccer players 
show a range of dementia subtypes. In some 
series, neuropathologic changes consistent with 
CTE have been described as occurring in 75% of 
former soccer and rugby players; however, such 
changes were infrequently the primary patho-
logic cause of dementia.13 Because of the lack of 
specific diagnostic coding for CTE, we were un-
Variable
Former Soccer Players  
or Matched Controls
Hazard Ratio or Odds Ratio 
(95% CI)* P Value
no./total no. (%)
Influence of player position on mortality
Mortality with neurodegenerative disease listed 
as the primary or a contributory cause
0.73 (0.43–1.24) 0.24†
Goalkeepers 15/104 (14.4)
Outfield players 180/873 (20.6)
Mortality with dementia not otherwise specified  
listed as the primary or a contributory cause
0.59 (0.31–1.12) 0.10†
Goalkeepers 10/104 (9.6)
Outfield players 148/873 (17.0)
Prescriptions of dementia-related medications‡
As assessed in both study cohorts 4.90 (3.81–6.31) <0.001§
Former players 199/7058 (2.8)
Matched controls 144/20,914 (0.7)
As assessed among former players according to 
player position
0.41 (0.19–0.89) 0.02¶
Goalkeepers 7/545 (1.3)
Outfield players 171/5581 (3.1)
*  Hazard ratios are given for the influence of player position on mortality and odds ratios for prescriptions of dementia­
related medications.
†  The P value was calculated with the use of a Cox proportional­hazards regression model.
‡  Prescription data were available from 2009 and were thus available for 7058 of 7676 former soccer players (91.9%) and 
20,914 of 23,028 matched controls (90.8%). Among the 7058 former soccer players, data regarding player position were 
available for 6126 (86.8%).
§  The P value was calculated with the use of a conditional logistic­regression model.
¶  The P value was calculated with the use of a standard logistic­regression model.
Table 4. Influence of Player Position on Mortality and Prescriptions of Dementia-Related Medications.
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able to make conclusions regarding its presence 
as either the primary diagnosis or a coexisting 
disease, but it may have been coded among 
other disorders, if diagnosed.
Death certificates are subject to errors in re-
porting. We sought to corroborate our findings 
on mortality from neurodegenerative disease and 
dementia by investigating the proportions of 
persons who received prescriptions of medica-
tions that are typically used for Alzheimer’s dis-
ease and related dementias. The findings from 
this analysis, showing that dementia-related 
medications were prescribed more frequently to 
former soccer players than to controls, supported 
the observations made from the comparison of 
death certificates.
A strength of this study was the inclusion of 
a comprehensive cohort of former Scottish pro-
fessional soccer players. We compared the out-
comes in this cohort with those of matched 
controls from the general population and ad-
justed our estimates for competing causes of 
death when calculating the risk of death from 
neurodegenerative causes. However, not all for-
mer players identified from the master data sets 
of professional soccer players could be matched 
to Community Health Index numbers. It is pos-
sible that differences between this group of play-
ers who could not be matched and the former 
players who were included in the study intro-
duced bias into our results. The relevance of our 
findings in elite athletes to recreational soccer 
participation is not known. These observations 
cannot be applied directly to recreational and 
amateur soccer players.
In summary, our data show that mortality 
from neurodegenerative disease was higher and 
prescriptions of dementia-related medications 
were more common among former professional 
soccer players than among controls from the 
Scottish population. The risk of death from neu-
rodegenerative disease varied according to disease 
subtype. Mortality from other common diseases 
was lower among former soccer players than 
among controls. These data need to be con-
firmed in prospective matched-cohort studies.
Supported by the Football Association and Professional Foot-
ballers’ Association and by an NHS Research Scotland Career 
Researcher Fellowship (to Dr. Stewart).
Disclosure forms provided by the authors are available with 
the full text of this article at NEJM.org.
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